Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Lapatinib + SCH772984 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lapatinib | Tykerb | Lapatinib Ditosylate | EGFR Inhibitor (Pan) 62 HER2 Inhibitor 42 | Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov). |
SCH772984 | SCH984|SCH-772984 | ERK Inhibitor (pan) 21 | SCH772984 is an ATP-competitive inhibitor of both ERK1 and ERK2, which may result in growth inhibition and tumor regression (PMID: 23614898, PMID: 32371878). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB3 T355I | estrogen-receptor positive breast cancer | no benefit | Lapatinib + SCH772984 | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Tykerb (lapatinib) and SCH772984 resulted in a synergistic effect, demonstrating decreased colony formation and reduced cell proliferation, but to a lesser degree than Tykerb (lapatinib) combined with Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB3 (HER3) T355I in culture (PMID: 29963236). | 29963236 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|